Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib
Abstract Adjuvant CDK4/6 inhibitors (abemaciclib and ribociclib) associated with endocrine therapy reduced the risk of relapse for HR+/HER2− early breast cancer (eBC) patients in the monarchE and NATALEE trials. In this population-based study, we assess the real-life proportion, and long-term progno...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-02-01
|
| Series: | npj Breast Cancer |
| Online Access: | https://doi.org/10.1038/s41523-025-00726-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571470798127104 |
|---|---|
| author | Sylvain Ladoire Ariane Mamguem Kamga Loick Galland Manon Reda Isabelle Desmoulins Didier Mayeur Courèche Kaderbhai Silvia Ilie Audrey Hennequin Henri Talucier Clementine Jankowski Charles Coutant Laurent Arnould Sandrine Dabakuyo |
| author_facet | Sylvain Ladoire Ariane Mamguem Kamga Loick Galland Manon Reda Isabelle Desmoulins Didier Mayeur Courèche Kaderbhai Silvia Ilie Audrey Hennequin Henri Talucier Clementine Jankowski Charles Coutant Laurent Arnould Sandrine Dabakuyo |
| author_sort | Sylvain Ladoire |
| collection | DOAJ |
| description | Abstract Adjuvant CDK4/6 inhibitors (abemaciclib and ribociclib) associated with endocrine therapy reduced the risk of relapse for HR+/HER2− early breast cancer (eBC) patients in the monarchE and NATALEE trials. In this population-based study, we assess the real-life proportion, and long-term prognosis of patients treated for HR+/HER2- eBC between 2005 and 2015, and eligible for adjuvant CDK4/6 inhibitors according to these trial inclusion criteria. Among 3,103 patients, N = 440 (14.2%) would have been eligible for adjuvant abemaciclib, and N = 1068 (34.4%) for ribociclib. Node-negative patients who would have been eligible for adjuvant ribociclib represent 10.9% of the eligible population. 21.7% of patients now eligible for adjuvant abemaciclib, and 32.1% for ribociclib did not receive (neo)adjuvant chemotherapy. After a median follow-up of 144.7 months, 10-year overall survival confirms the prognostic relevance of the inclusion criteria used in pivotal trials. This study provides real-life insights into the prevalence, clinicopathological characteristics and long-term prognosis of HR+/HER2− eBC patients now eligible for adjuvant CDK4/6 inhibitors. |
| format | Article |
| id | doaj-art-b57642fa4f544b34b48854b4fa1fab75 |
| institution | Kabale University |
| issn | 2374-4677 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Breast Cancer |
| spelling | doaj-art-b57642fa4f544b34b48854b4fa1fab752025-02-02T12:35:29ZengNature Portfolionpj Breast Cancer2374-46772025-02-011111910.1038/s41523-025-00726-xPrevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclibSylvain Ladoire0Ariane Mamguem Kamga1Loick Galland2Manon Reda3Isabelle Desmoulins4Didier Mayeur5Courèche Kaderbhai6Silvia Ilie7Audrey Hennequin8Henri Talucier9Clementine Jankowski10Charles Coutant11Laurent Arnould12Sandrine Dabakuyo13Department of Medical Oncology, Centre Georges-François Leclerc, 1 rue du Professeur MarionCôte d’Or Breast and Gynecological Cancer Registry, George-François Leclerc Cancer CentreDepartment of Medical Oncology, Centre Georges-François Leclerc, 1 rue du Professeur MarionDepartment of Medical Oncology, Centre Georges-François Leclerc, 1 rue du Professeur MarionDepartment of Medical Oncology, Centre Georges-François Leclerc, 1 rue du Professeur MarionDepartment of Medical Oncology, Centre Georges-François Leclerc, 1 rue du Professeur MarionDepartment of Medical Oncology, Centre Georges-François Leclerc, 1 rue du Professeur MarionDepartment of Medical Oncology, Centre Georges-François Leclerc, 1 rue du Professeur MarionDepartment of Medical Oncology, Centre Georges-François Leclerc, 1 rue du Professeur MarionDepartment of Medical Oncology, Centre Georges-François Leclerc, 1 rue du Professeur MarionDepartment of Surgical Oncology Centre Georges-François Leclerc 1 rue du Professeur MarionUniversity of Burgundy-Franche ComtéDepartment of Biology and Pathology of Tumors. Centre Georges-François Leclerc, 1 rue du Professeur MarionCôte d’Or Breast and Gynecological Cancer Registry, George-François Leclerc Cancer CentreAbstract Adjuvant CDK4/6 inhibitors (abemaciclib and ribociclib) associated with endocrine therapy reduced the risk of relapse for HR+/HER2− early breast cancer (eBC) patients in the monarchE and NATALEE trials. In this population-based study, we assess the real-life proportion, and long-term prognosis of patients treated for HR+/HER2- eBC between 2005 and 2015, and eligible for adjuvant CDK4/6 inhibitors according to these trial inclusion criteria. Among 3,103 patients, N = 440 (14.2%) would have been eligible for adjuvant abemaciclib, and N = 1068 (34.4%) for ribociclib. Node-negative patients who would have been eligible for adjuvant ribociclib represent 10.9% of the eligible population. 21.7% of patients now eligible for adjuvant abemaciclib, and 32.1% for ribociclib did not receive (neo)adjuvant chemotherapy. After a median follow-up of 144.7 months, 10-year overall survival confirms the prognostic relevance of the inclusion criteria used in pivotal trials. This study provides real-life insights into the prevalence, clinicopathological characteristics and long-term prognosis of HR+/HER2− eBC patients now eligible for adjuvant CDK4/6 inhibitors.https://doi.org/10.1038/s41523-025-00726-x |
| spellingShingle | Sylvain Ladoire Ariane Mamguem Kamga Loick Galland Manon Reda Isabelle Desmoulins Didier Mayeur Courèche Kaderbhai Silvia Ilie Audrey Hennequin Henri Talucier Clementine Jankowski Charles Coutant Laurent Arnould Sandrine Dabakuyo Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib npj Breast Cancer |
| title | Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib |
| title_full | Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib |
| title_fullStr | Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib |
| title_full_unstemmed | Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib |
| title_short | Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib |
| title_sort | prevalence clinicopathologic features and long term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and or ribociclib |
| url | https://doi.org/10.1038/s41523-025-00726-x |
| work_keys_str_mv | AT sylvainladoire prevalenceclinicopathologicfeaturesandlongtermoverallsurvivalofearlybreastcancerpatientseligibleforadjuvantabemaciclibandorribociclib AT arianemamguemkamga prevalenceclinicopathologicfeaturesandlongtermoverallsurvivalofearlybreastcancerpatientseligibleforadjuvantabemaciclibandorribociclib AT loickgalland prevalenceclinicopathologicfeaturesandlongtermoverallsurvivalofearlybreastcancerpatientseligibleforadjuvantabemaciclibandorribociclib AT manonreda prevalenceclinicopathologicfeaturesandlongtermoverallsurvivalofearlybreastcancerpatientseligibleforadjuvantabemaciclibandorribociclib AT isabelledesmoulins prevalenceclinicopathologicfeaturesandlongtermoverallsurvivalofearlybreastcancerpatientseligibleforadjuvantabemaciclibandorribociclib AT didiermayeur prevalenceclinicopathologicfeaturesandlongtermoverallsurvivalofearlybreastcancerpatientseligibleforadjuvantabemaciclibandorribociclib AT courechekaderbhai prevalenceclinicopathologicfeaturesandlongtermoverallsurvivalofearlybreastcancerpatientseligibleforadjuvantabemaciclibandorribociclib AT silviailie prevalenceclinicopathologicfeaturesandlongtermoverallsurvivalofearlybreastcancerpatientseligibleforadjuvantabemaciclibandorribociclib AT audreyhennequin prevalenceclinicopathologicfeaturesandlongtermoverallsurvivalofearlybreastcancerpatientseligibleforadjuvantabemaciclibandorribociclib AT henritalucier prevalenceclinicopathologicfeaturesandlongtermoverallsurvivalofearlybreastcancerpatientseligibleforadjuvantabemaciclibandorribociclib AT clementinejankowski prevalenceclinicopathologicfeaturesandlongtermoverallsurvivalofearlybreastcancerpatientseligibleforadjuvantabemaciclibandorribociclib AT charlescoutant prevalenceclinicopathologicfeaturesandlongtermoverallsurvivalofearlybreastcancerpatientseligibleforadjuvantabemaciclibandorribociclib AT laurentarnould prevalenceclinicopathologicfeaturesandlongtermoverallsurvivalofearlybreastcancerpatientseligibleforadjuvantabemaciclibandorribociclib AT sandrinedabakuyo prevalenceclinicopathologicfeaturesandlongtermoverallsurvivalofearlybreastcancerpatientseligibleforadjuvantabemaciclibandorribociclib |